 |
|
|
|
 |
| Health Library |
|
 |
|
Cast Your Vote Here Once A Month to make a difference in the life of someone with CF!
more > |
|
|
|
| |
Feature
Brand Awareness Survey Results.
The results of the Brand Awareness Survey was a success with 637 community members
answering the survey in less than 5 days. Our overall findings were intriguing. Results showed
that although many people are familiar with some products, many have not been successfully
informed about their functions or the benefits of proper compliance or adherence. This
highlights the need for additional education regarding those products and what they are used
for. In an effort to empower the community, CysticFibrosis.com is taking what we learned from
these results and have begun discussions with notable healthcare industry leaders and
practitioners on how they might be able to help reach the needs and better inform
our community.
If you have any questions or would like more information regarding our research efforts,
please contact us at research@cysticfibrosis.com
Age of Respondents
Of the 637 respondents, 40% were individuals that have cystic fibrosis and 48% were care givers for someone with cystic fibrosis. Age range of the person with cystic fibrosis (individual respondent or the individual the caregiver provides for) varied, though most were in the 19 to 35 year old bracket (39%), or the 0 to 12 year old bracket (34%).
|
| |
 |
 |
| |
Pulmozyme/Hypertonic Saline
Analysis indicates that many respondents are uninformed about what Pulmozyme and
Hypertonic Saline are designed to do. 66% of respondents stated they either do not know what
the differences are between Pulmozyme and Hypertonic Saline, or they believe the two
medications do the same thing. Though in some cases respondents indicated their physician
does not prescribe Pulmozyme or it is not an applicable treatment for them, the majority of
respondents are unfamiliar with the purpose and results of both Pulmozyme and Hypertonic
Saline. 42% of respondents indicated they would like to be better informed about Pulmozyme. |
 |
 |
 |
 |
 |
 |
|
 |
| |
PARI eFlow
In review of the analysis, trends indicate that nearly 1 out of 5 (18%) respondents are currently
using the PARI eFlow product. The remaining 4 out of 5(82%) that don’t use the eFlow are
either unaware or would like more information about the product. Cysticfibrosis.com was the
second highest source for where individuals first learned about the eFlow. |
 |
 |
 |
 |
 |
| |
Smiths Medical Acapella Choice and Acapella Duet
Analysis shows that 1 out of 6 (17%) respondents are currently using the Acapella choice
product. The remaining 5 out of 6 (83%) have either never heard of the product or have chosen
not to use it. When asked about the newest Smiths Medical PEP therapy system, the Acapella
Duet, majority of respondents (93%) were not aware of the product. |
 |
 |
| |
Ambry Genetics and Genetic Testing
In review of the findings, more than two-thirds of the respondents (68%) received genetic
testing for Cystic Fibrosis while the others did not or could not recall what form of testing they
received. In regards to the Ambry Genetics genetic test, CF Amplified, the majority of
respondents are unaware of the product’s accuracy and completeness of identifying 99% of all
the 1,500+ known genetic mutations today. |
 |
 |
 |
 |
| |
Online Drug Purchases
Analysis indicates that 50% of respondents purchase their medications and medical equipment
from their local pharmacy, while 31% purchase from online pharmacies. When asked to
explain their reasons for not purchasing online, 5% indicated their insurance would not cover
the purchase, 38% indicated they previously had a bad experience or had difficulty trusting an
online pharmacy, while the remaining 57% felt the current method they use to purchase
medications and medical equipment met their needs. |
 |
 |
 |
 |
| |
< Back to newsletter home page |
|
|
|
|
|
|
|
|
